Search results

Skip to results

Type

Status

Last updated

Showing 1 to 13 of 13 results for ocrelizumab

  1. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    25 July 2018
    View recommendations

    Sections for TA533

  2. Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    12 June 2019
    View recommendations

    Sections for TA585

  3. Ublituximab for treating relapsing multiple sclerosis (TA1025)

    Evidence-based recommendations on ublituximab (Briumvi) for treating relapsing multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    18 December 2024
    View recommendations

    Sections for TA1025

  4. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

    Technology appraisal guidance
    Published
    19 May 2021
    View recommendations

    Sections for TA699

  5. Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)

    Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    15 April 2025
    View recommendations

    Sections for TA1053

  6. Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)

    Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.

    Technology appraisal guidance
    Published
    9 June 2021
    View recommendations

    Sections for TA706

  7. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

    Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    19 February 2020
    View recommendations

    Sections for TA624

  8. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]

    In development [GID-TA10977] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  10. Ocrelizumab for treating relapsing–remitting multiple sclerosis in people 10 to 17 years [TSID12164]

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)

    Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA767

  12. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

    Medtech innovation briefing
    Published
    29 March 2022

  13. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued [GID-TA10099]

    Technology appraisal guidance
    Discontinued